Agilent Partners with the Advanced Cell Therapy and Research Institute in Singapore

Agilent is partnering with the Advanced Cell Therapy and Research Institute in Singapore (ACTRIS) to advance the development of cell and gene therapies over the next three years, the company said in a press release earlier this month (1).

As part of the partnership, the company will install and operate its xCELLigence real-time cell analyzer, Seahorse XF technology, and other cell analysis portfolio at the Institute, which is the largest national cell and gene therapy process development and manufacturing facility in Singapore. ACTRIS will also receive early access to Agilent’s new cell analysis platform, which will facilitate the development of cell therapies for market authorization.

Agilent has had investments in Singapore for over 20 years, with more than 600 scientists, engineers, and employees in the country. The company facilities there include a Fourth Industrial Revolution (4IR) accredited manufacturing plant, an Agilent University, and a Global Solutions Development Center where its local scientists develop integrated end-to-end workflow methods and novel applications for projects.

Reference

(1) Agilent. Agilent and ACTRIS Partner to Accelerate Cell and Gene Therapy in Singapo nnnnre.Agilent 2023. https://www.agilent.com/about/newsroom/presrel/2023/04sep-ca23035.html(accessed 2023-09-11)